WASHINGTON (PRWEB)
May 15, 2023
Mctlaw won more than $2 million in Vaccine Injury Compensation Program awards for 12 of our vaccine injury clients since January. These clients experienced severe life altering reactions, including: Intussusception, Shoulder Injury Related to Vaccine Administration (SIRVA), Acute Disseminated Encephalomyelitis (ADEM), Guillain-Barré Syndrome (GBS), and Thrombocytopenic Purpura. The vaccines that caused these reactions are: flu, rotavirus, TDaP, MMR, and varicella. The largest award amount is $721,446.78 for a client with ADEM.
Our vaccine injury case results table includes data from 835 cases, with the type of vaccine, type of reaction, and the amount won for the client. This data is updated quarterly. In total, mctlaw vaccine injury attorneys have won hundreds of millions of dollars for our clients.
The Vaccine Injury Compensation Program (VICP) is a federal program that awards payouts to people who’ve had serious side effects from covered immunizations. Vaccine injury cases are heard in the United States Court of Federal Claims in Washington, DC, just blocks away from mctlaw’s DC office. The VICP’s four-billion dollar trust fund is paid for by a seventy-five cent tax on every vaccine administered in the U.S.
The vaccine injury attorneys at mctlaw have won more than $300-million dollars for our clients across the country, including the highest compensation award ever given in the history of the VICP. Clients never pay legal fees for our representation. The Court pays all of our legal fees and clients keep the entire amount of their settlements.
About mctlaw:
Mctlaw is a national leader in vaccine injury litigation and represents clients across the country. We aggressively fight for our clients and guide them through disputes to resolution, with hundreds of millions of dollars won in judgments. The Firm’s offices are in Washington, DC; Sarasota, FL; and Seattle, WA. If you think you have a severe vaccine injury, contact us at 888-952.5242. Learn more at mctlaw.com/vaccine-injury/.
Share article on social media or email: